NAICS Classification 325412 Government Contracts

Solicitation M5Q50A03R8 for 6505--Wilshire Pharmaceuticals, 36F79726D0208, Schedule 65 I B Effective Dates: 09/29/2026 -09/28/2031 published by VETERANS AFFAIRS, DEPARTMENT OF. Prospective offerors must consult official solicitation documents on SAM.gov for full instructions, specifications, and submission deadlines.

Solicitation AddFullContractHere for 6505--Deciphera Pharmaceuticals LLC (65IB), 36F79726D0211, Effective 09/29/2026 - 09/28/2031 published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

Solicitation AddFullContractHere for 6505--Deciphera Pharmaceuticals LLC (65IB), 36F79726D0211, Effective 09/29/2026 - 09/28/2031 published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

The Department of Veterans Affairs, NCO 4 Contracting Office has awarded a firm-fixed priced contract for a base year with (4) option years, exercisable at the Government s discretion to provide Fluorodeoxyglucose (FDG) Radiopharmaceuticals for Philadelphia VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104. The total estimated value of award is $637,630.00.

The Department of Veterans Affairs, NCO 4 Contracting Office has awarded a firm-fixed priced contract for a base year with (4) option years, exercisable at the Government s discretion to provide Fluorodeoxyglucose (FDG) Radiopharmaceuticals for Philadelphia VA Medical Center, 3900 Woodland Ave, Philadelphia, PA 19104. The total estimated value of award is $637,630.00.

Page 1 AWARD NOTICE In accordance with (IAW) FAR 5.101, this notice is to advise the public that the Veterans Health Administration (VHA), Network Contracting Office 23, awarded a contract action exceeding $25,000.00 for Rh-82 Rhubidium Generators for the Iowa City VA Health Care System. The award was made to only one Federal Supply Schedule (FSS) source under the ordering procedures prescribed in GSAR Subpart 538.71, including GSAR 538.7103-3 and the sole source justification requirements at GSAR 538.7104-3(b). This notice is not a request for competitive quotations. The intended procurement is classified under North American Industry Classification System (NAICS) Code 325412. For additional information regarding this action, please contact the point of contact identified above. IAW GSAR 538.7104-3(b)(3), the redacted sole source justification for this award has been attached to this notice and made publicly available in accordance with the applicable publication requirements.

Solicitation 36C25027D0004 for 6505--Supplies - Radioactive Isotopes - Ann Arbor published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

Solicitation 36C24427D0003 for 6505--Lab Supplies | Radiopharm | New 5 year consolidation Lebanon & Pittsburgh - Illuccix | 595 and 646 | EDA: 10/01/2026 VLD | Status: moved to collaboration, once actionable will be assigned to Christa S, CO Cindy L (7/16/2 (VA-27-00002334) published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

A list of each contractor and the corresponding contract number for awards made under RFP No. 75A50326R00007: Fresenius Kabi, LLC: Three Corporate Drive, Lake Zurich, IL 60047; Contract #: 75A50326C00007 LogMet LLC: 1311 Chisholm Trail RD, Round Rock, Texas; Contract #: 75A50326C00008 Paragon Enterprises Inc.: 3300 Corporate Avenue, Weston, FL; Contract #: 75A50326C00009 Chartwell Rx LLC: 77 Brenner Dr, Congers, New York; Contract #: 75A50326C00010 The Stronghold Group LLC: 3409 B Ainslie St, Philadelphia, Pennsylvania; Contract #: 75A50326C00011 Hikma Pharmaceuticals USA Inc.: 200 Connell Drive, Berkeley Heights, NJ; Contract #: 75A50326C00012 Lovell Government Services Inc.: 223 W Gregory Street, Pensacola, FL; Contract #: 75A50326C00013 SouthernBelle Room, LLC: 2001 Martin Luther King Jr Drive SW, Atlanta, GA; Contract #: 75A50326C00014

Solicitation 36C25626Q1210 for 6505--Radiopharmaceuticals published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

The contract was not awarded competitively in accordance with Revolutionary FAR Overhaul (RFO) 12.102(a) - acquisitions valued at or below the simplified acquisition threshold.

Solicitation SPE2D223D0012 for Quetiapine Fumarate XR Tablets published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

Solicitation 36E79726R0037 for 6505--Prednisolone 1% Ophthalmic Solution published by DEPT OF DEFENSE. Contractors must submit responses conforming to the requirements in the official SAM.gov solicitation notice and associated attachments.

THIS IS NOT A REQUEST FOR COMPETITIVE OFFERS Philadelphia VA Medical Center This is a Pre-Solicitation Notice for the Department of Veterans Affairs, Network Contracting Office (NCO) 4, radiopharmaceuticals and calibration sources for the Nuclear Medicine Department at the Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104. The full solicitation will be posted on the Contract Opportunities website at www.sam.gov on or about October 8th, 2026. The full solicitation will be unrestricted. The North American Industry Classification System (NAICS) for this procurement is 325412: the size standard is 1000 employees. Potential offerors are responsible for monitoring this site for the release of the solicitation package and any other pertinent information and for downloading their own copy of the solicitation package. Any amendments issued to this solicitation will ONLY be available on this site. Offerors are advised that they are responsible for obtaining all amendments. All questions must be submitted in writing to the Contracting Officer at [email protected]. No telephone inquiries will be accepted. This notice does not obligate the Government to award a contract neither does it obligate the Government to pay for any quotes or proposal preparation costs. The Government is not obligated to issue a solicitation because of this notice. No other information is available until issuance of the solicitation. All interested parties must be registered in System for Award Management (SAM) pursuant to applicable regulations and guidelines prior to award. Registration information can be found at www.sam.gov. The point of contact is Contracting Officer, Keri Hester, email: [email protected].

Presolicitation Notice Page 1 of 4 Presolicitation Notice *=Required Field Presolicitation Notice Page 1 of 2 PRE-SOLICITATION NOTICE:  The VA Enterprise Procurement Office intends to issue Request for Proposal (RFP) 36E79726R0037 for an unrestricted procurement for Prednisolone Acetate 1% Ophthalmic Suspension, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD) (inclusive of Tricare Mail Order Pharmacies (TMOPs)), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).  VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. One or more of the items under this acquisition is subject to the World Trade Organization Government Procurement Agreement and Free Trade Agreements.  Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor s label.  The bottle must fit a label with a dimension of 5.25 x 2 . The 0.5  additional space is required to keep the bar code exposed and/or allow for the display of the expiration date and lot number. Solicitation # 36E79726R0037 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about October 01, 2026, with a tentative closing date of October 15, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Michael Olszewski. Questions can be e-mailed to [email protected].   The estimated annual requirements are as follows:  The estimated annual requirements are as follows: ITEM DESCRIPTION PACKAGE SIZE (ML) TOTAL ESTIMATED ANNUAL USAGE (Bottles) 1 PREDNISOLONE ACETATE 1% SUSP,OPH 5 392,107 2 PREDNISOLONE ACETATE 1% SUSP,OPH 10 70,070 3 PREDNISOLONE ACETATE 1% SUSP,OPH 15 10,172

This notice is being published in accordance with Revolutionary FAR Overhaul Federal Acquisition Regulation (RFO FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. The Network Contracting Office (NCO) 2, Department of Veterans Affairs intends to award a firm-fixed-price sole source contract with Novartis Pharmaceuticals Corporation, a large business, for the purchase of 18 units of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) and 4 units of Lutathera (Lutetium Lu 177 Dotatate) for VA Western New York Healthcare System Buffalo VA Medical Center Nuclear Medicine 3495 Bailey Avenue Buffalo, NY 14215 This sole source determination is in accordance with GSAM/R 538.7104-3(b)(1)(ii), Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. Novartis Pharmaceuticals Corporation is the only known authorized supplier for Pluvicto and Lutathera. The North American Industry Classification System (NAICS) code for this procurement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. Statement of Need: The New York/New Jersey Healthcare System Veterans Integrated Service Network (VISN) 2, in support of VA Buffalo Medical Center has a requirement for 18 units of Pluvicto, a radioactive therapy treatment for Prostate-specific Membrane Antigen-Positive Metastatic Castration-Resistant Prostate Cancer (PSMA-Positive mCRPC), and 4 units of Lutathera, a peptide receptor radionuclide therapy (PRRT) designed to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. If your firm provides the radiopharmaceutical therapy on GSA Federal Supply Schedule or any Federal Supply Schedule, please provide applicable contract number and identify which supply/service are applicable to that FSS contract, and the following additional information (1) A tailored capability statement indicating the firm s ability to provide a product and related services; (2) The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc.,) pursuant to the applicable NAICS code; (3) Information should be provided electronically. Potential offerors must be a manufacturer or fully licensed, authorized distributor for the radiopharmaceutical items. Potential offerors must be FDA certified. This notice of intent is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to the requirement and submit capability statement no later than 4:00 pm., ET, Thursday October 15, 2026, to [email protected]. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses received to this notice is solely within the discretion of the Government. If no written response is received within the closing date of this notice, a single source delivery order award will be made to Novartis Pharmaceuticals Corporation without any further notice. This notice does not obligate the Government to award an agreement or otherwise pay for the information provided in response to this notice. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work.

PRE-SOLICITATION NOTICE: The VA Enterprise Procurement Office intends to issue Request for Proposal (RFP) 36E79727R0039 for an unrestricted procurement for Latanoprost Ophthalmic Solution, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD) (inclusive of Tricare Mail Order Pharmacies (TMOPs)), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. One or more of the items under this acquisition is subject to the World Trade Organization Government Procurement Agreement and Free Trade Agreements. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor s label. The vendor must follow the American Academy of Ophthalmology s recommended uniform color-coding system for the caps and labels of all topical ocular medications. https://www.aao.org/about/policies/color-codes-topical-ocular-medications Solicitation # 36E79727R0039 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about October 21, 2026, with a tentative closing date of November 4, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is James Sullivan. Questions can be e-mailed to [email protected]. The estimated annual requirements are as follows:

PRE-SOLICITATION NOTICE: The VA Enterprise Procurement Office intends to issue Request for Proposal (RFP) 36E79726R0036 for an unrestricted procurement for Imatinib Mesylate Tablet, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD) (inclusive of Tricare Mail Order Pharmacies (TMOPs)), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. One or more of the items under this acquisition is subject to the World Trade Organization Government Procurement Agreement and Free Trade Agreements. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor s label. All unit of use packaging identified in the Schedule of Supplies, (Line items 1 - 2, 30 and 90 count bottles) shall contain a safety-cap capable of having the outer part of the cap deshelled and / or a convertible cap to produce a non-safety cap and a bottle with a minimum required size of 120cc volume. The safety cap must not exceed the diameter of the bottle. The bottle must have a cylindrical body and minimum of 5.75 circumference. The bottle must fit a label with a dimension of 5.25 x 2 . The 0.5 additional space is required to keep the bar code exposed and/or allow for the display of the expiration date and lot number. Solicitation # 36E79726R0036 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about October 16, 2026, with a tentative closing date of October 30, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Andrew Cazares. Questions can be e-mailed to [email protected]. The estimated annual requirements are as follows: REQUIREMENT DESCRIPTION ITEM DESCRIPTION PACKAGE SIZE (Tablets per Bottle) TOTAL ESTIMATED ANNUAL USAGE (Bottles) 1 Imatinib Mesylate 100MG Tablet 90 6,397 2 Imatinib Mesylate 400MG Tablet 30 23,212

The federal government has issued this official active requirement (36F79726D0212) on SAM.gov. Complete technical specifications, statements of work, evaluation criteria, and attachments are accessible directly on the authoritative federal record.

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.